Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06328738 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv10
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 31 of 31 sites
    v9
  3. Study sites: 30 to 31v8
  4. Study sites: 29 to 30v7
  5. Enrollment target: 255 to 275
    • Study description expanded, about 8 words
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 8 to 29v5
  2. Study sites: 2 to 8v4
  3. Study sites: 1 to 2
    • Start date changed from estimate of Jun 1, 2024 to May 30, 2024
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Enliven Therapeutics
4 trials monitored
See all monitored trials
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
and 1 more disease
The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.
Trial Details
NCT Number NCT06328738
Lead Sponsor Enliven Therapeutics
Conditions
(from sponsor)		 HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 275 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov